Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Danshensu is a salvianolic acid and the major component of S. miltiorrhiza (Danshen) and has diverse biological activities.1,2,3,4 It reduces expression of the autophagy-associated proteins p62, LC3-II, and Beclin-1 and the apoptosis-related proteins Bax and caspase-3, prevents cardiomyocyte damage, and increases heart rate, coronary flow (CF), and left ventricular developed pressure (LVDP) in an isolated rat heart model of ischemia and reperfusion injury.1 Danshensu (60 mg/kg per day) reduces infarct size and improves left ventricular function in a rat model of myocardial infarction.2 It enhances radiation-induced tumor cell death in a Lewis lung carcinoma mouse xenograft model.3 Danshensu also decreases infarct volume, neuronal apoptosis, production of TNF-α, IL-1β, and IL-6, and superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity in a rat model of cerebral ischemia and reperfusion injury.4
WARNING This product is not for human or veterinary use.
1. Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling. J. Cell Mol. Med. 20(10), 1908-1919 (2016).
2. Danshensu accelerates angiogenesis after myocardial infarction in rats and promotes the functions of endothelial progenitor cells through SDF-
3. Danshensu, a major water-
4. Synergistic neuroprotective effects of Danshensu and hydroxysafflor yellow A on cerebral ischemia-